Catalyst Pharmaceuticals to Release Financial Results
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), a key player in the biopharmaceutical sector, is set to disclose its financial performance for the second quarter of 2025 following market closure. This report will be made public on August 6, 2025. With a dedicated focus on rare and challenging diseases, Catalyst aims to shed light on its advancements and strategies during this period.
Conference Call and Webcast Details
On August 7, 2025, the management will hold a conference call and an online webcast at 8:30 AM ET to discuss the financial results and provide a comprehensive update on the company’s business strategies. Stakeholders and interested parties can tune into this session to gain valuable insights into Catalyst's ongoing projects and financial health.
Accessing the Webcast
Investors can access the live webcast through the Investor Relations section of Catalyst Pharmaceuticals' official website. A recorded version will be available for playback at least 30 days post-event, ensuring that all stakeholders stay informed about the company's direction and updates.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. is committed to enhancing the lives of individuals suffering from rare diseases. With an impressive portfolio of innovative therapies that have already changed lives, Catalyst emphasizes in-licensing and developing unique treatment solutions to meet the ongoing needs of patients. The company's strategic focus on making treatments accessible is pivotal, allowing them to provide ongoing support and care for patients reliant on their medications.
Recently recognized on Forbes' list of America’s Most Successful Mid-Cap Companies, Catalyst is also noted on Deloitte's Technology Fast 500 as one of North America's fastest-growing firms. This recognition signifies the company's resilience and ability to adapt in a competitive biopharmaceutical landscape.
Corporate Headquarters and Contact Information
Catalyst Pharmaceuticals is headquartered in Coral Gables, Florida, maintaining a strong presence in the United States. For investor inquiries, contact Mary Coleman at (305) 420-3200. Media inquiries can be directed to David Schull at Russo Partners by calling (858) 717-2310.
Frequently Asked Questions
What are Catalyst Pharmaceuticals' main areas of focus?
Catalyst Pharmaceuticals primarily focuses on developing and commercializing therapies for rare diseases, ensuring that innovative treatments are brought to market.
When will the Q2 2025 financial results be released?
The financial results are scheduled to be released on August 6, 2025, after the market closes.
How can stakeholders access the conference call?
Interested parties can access the conference call and webcast via the Investor Relations section of Catalyst Pharmaceuticals' website on August 7, 2025.
What recent achievements has Catalyst Pharmaceuticals attained?
Catalyst has been recognized as one of America's Most Successful Mid-Cap Companies and listed among North America's Fastest-Growing Companies by Deloitte.
Who should be contacted for investor-related queries?
Mary Coleman, the investor relations contact for Catalyst Pharmaceuticals, can be reached at (305) 420-3200 for any investor-related inquiries.
